A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• R.E. Sanborn, J.D. Patel, G.A. Masters, N. Jayaram, A.W. Stephens, M.J. Guarino, J.G. Misleh, C.E. Williams, J.Wu, N.H. Hanna. A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC): Hoosier Oncology Group LUN06-113. Presented at the oral abstract session, lung cancer – non-small cell local-regional/small cell/other thoracic cancers at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 7506). See abstract.
• Sanborn, R. E., Patel, J. D., Masters, G. A., Jayaram, N., Stephens, A., Guarino, M., Misleh, J., Wu, J. and Hanna, N. (2016), A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer. doi:10.1002/cncr.30287. See abstract.